Table 3 –
Incremental cost-effectiveness ratios.
| Base case and subgroups | Replication cost ($) | Incremental cost ($) | Adherence (%)* | Incremental adherence (%) | ICER ($) |
|---|---|---|---|---|---|
| Cost-effectiveness for those taking ACEIs/ARBs | |||||
| Base case | |||||
| Control group (n = 4331) | 51.38 | 58 | |||
| Intervention IVR group (n = 4374) | 61.04 | 9.66 | 59 | 1.7 | 5.78 |
| Intervention IVR+ group (n = 4331) | 90.02 | 28.98 | 61 | 1.9 | 15.58 |
| Subgroup analysis: Baseline adherence <50% | |||||
| Control group (n = 2164) | 37.88 | 45 | |||
| Intervention IVR group (n = 2133) | 47.54 | 9.66 | 47 | 1.9 | 5.22 |
| Intervention IVR+ group (n = 2127) | 75.54 | 28.00 | 50 | 2.9 | 9.59 |
| Subgroup analysis: Individuals with baseline cost higher than the median | |||||
| Control group (n = 2195) | 49.01 | 57 | |||
| Intervention IVR group (n = 2277) | 60.52 | 11.51 | 58 | 1.7 | 6.65 |
| Intervention IVR+ group (n = 2236) | 88.68 | 28.16 | 60 | 1.5 | 18.41 |
| Subgroup analysis: Receiving/qualifying for two calls or more | |||||
| Control group (n = 4000) | 52.98 | 59 | |||
| Intervention IVR group (n = 2835) | 65.90 | 12.92 | 64 | 5.2 | 2.49 |
| Intervention IVR+ group (n = 2661) | 97.59 | 31.69 | 67 | 2.8 | 11.20 |
| Cost-effectiueness for those taking statins | |||||
| Base case | |||||
| Control group (n = 5486) | 120.93 | 55 | |||
| Intervention IVR group (n = 5460) | 135.74 | 14.81 | 57 | 2.4 | 6.24 |
| Intervention IVR+ group (n = 5434) | 163.76 | 28.02 | 58 | 0.7 | 42.64 |
| Subgroup analysis: Baseline adherence <50% | |||||
| Control group (n = 2852) | 92.24 | 52 | |||
| Intervention IVR group (n = 2856) | 110.25 | 18.01 | 55 | 3.0 | 6.08 |
| Intervention IVR+ group (n = 2815) | 128.84 | 18.59 | 56 | 0.8 | 23.83 |
| Subgroup analysis: Individuals with baseline cost higher than the median | |||||
| Control group (n = 2713) | 114.06 | 55 | |||
| Intervention IVR group (n = 2705) | 135.08 | 21.02 | 58 | 2.8 | 7.56 |
| Intervention IVR+ group (n = 2708) | 159.29 | 24.21 | 58 | 0.15 | 161.40 |
| Subgroup analysis: Receiving/qualifying for two calls or more | |||||
| Control group (n = 5031) | 123.21 | 56 | |||
| Intervention IVR group (n = 3525) | 148.56 | 25.35 | 62 | 6.3 | 4.00 |
| Intervention IVR+ group (n = 3320) | 177.36 | 28.80 | 63 | 1.4 | 20.00 |
| Replication cost ($) | Incrementalcost ($) | LDL level | Incremental change in LDL level | ICER ($) | |
|---|---|---|---|---|---|
| LDL cost-effectiueness for those taking statins | |||||
| Base case | |||||
| Control group (n = 4621) | 130.52 | 92.3 | |||
| Intervention IVR group (n = 4610) | 146.29 | * | 92.1 | * | * |
| Intervention IVR+ group (n = 4545) | 174.48 | 28.19 | 91.1 | −1.0 | 28.77 |
| Subgroup analysis: Baseline adherence <50% | |||||
| Control group (n = 2392) | 102.82 | 92.6 | |||
| Intervention IVR group (n = 2416) | 121.99 | * | 92.3 | * | * |
| Intervention IVR+ group (n = 2312) | 139.90 | 17.91 | 91.3 | −1.1 | 16.90 |
| Subgroup analysis: Baseline LDL >100 mg/dl | |||||
| Control group (n = 1352) | 120.26 | 114.5 | |||
| Intervention IVR group (n = 1329) | 122.12 | 1.86 | 114.0 | −0.5 | 3.74 |
| Intervention IVR+ group (n = 1346) | 152.86 | 30.74 | 111.5 | −2.5 | 12.13 |
| Subgroup analysis: Receiving/qualifying for two calls or more | |||||
| Control group (n = 4301) | 131.02 | 91.9 | |||
| Intervention IVR group (n = 3139) | 154.06 | 23.04 | 90.0 | −1.9 | 12.33 |
| Intervention IVR+ group (n = 2946) | 181.90 | 27.84 | 89.0 | −1.0 | 28.12 |
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; ICER, incremental cost-effectiveness ratio; IVR, interactive voice recognition; IVR+, IVR plus educational materials; LDL, low-density lipoprotein.
*
Intervention is dominated.